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Background: Left ventricular hypertrophy (LVH) has been shown to be an independent risk factor for cardiovascular outcomes. We sought to 
assess the association between the novel biomarkers and LVH in a multiethnic population.
Methods: Multi-Ethnic study of Atherosclerosis (MESA) is a population based study (n=6,814) of subjects aged 45-84 yrs, free from clinical CVD. 
We did a post-hoc analysis of the NHLBI limited access dataset of MESA subjects with information on all the studied biomarkers (n=708). LV mass 
was determined by cardiac MRI. LVH was defined as LV mass >= 53g/m2.7 in men and >= 47g/m2.7 in women. Logistic regression analysis was 
done adjusting for traditional cardiovascular risk factors.
Results: The mean age was 60 ±10 yrs; 43% were males, 38% were Whites, 28% were Blacks, 22% were Chinese, 12% were Hispanics and 38% 
were hypertensives. In univariate analyses, C-reactive protein, interleukin-6, E-selectin, soluble thrombomodulin, soluble tumor necrosis factor 
receptor (sTNFR) and intercellular adhesion molecule (ICAM) were significantly associated with LVH. In multivariate analysis, ICAM (odds ratio (OR) 
=1.006, 95% C.I=1.002 to 1.010, p=0.01) and sTNFR (OR=1.96, 95% C.I=1.09 to 3.54, p=0.03) were significantly associated with LVH, but other 
biomarkers were not (Table). There were no graded relationship with respect to sTNFR or ICAM quartiles and LVH.
Conclusion: Systemic overexpression of sTNFR and ICAM are strongly associated with LVH independent of standard cardiovascular risk factors.
Odds ratio of LVH categorized by inflammatory markers (selected shown)
Inflammatory markers Mean ± S.D Odds Ratio 95% C.I p-value
1. ICAM-1 (ng/ml) 282.3 ± 80.0 1.006 1.002 to 1.010 0.01
2. sTNFR (pg/ml) 1.3 ± 0.4 1.96 1.09 to 3.54 0.03
3. IL-6 (pg/ml) 1.4 ± 1.1 1.04 0.70 to 1.53 0.86
4. C-RP (mg/l) 3.6 ± 5.2 1.01 0.96 to 1.07 0.85
5. Soluble TM (ng/ml) 38.0 ± 20.6 1.01 0.99 to 1.03 0.18
ICAM: intercellular adhesion molecule; sTNFR: soluble tumor necrosis factor; IL: interleukin; C-RP: c-reactive protein; TM: thrombomodulin. 
Other biomarkers measured were fibrinogen antigen, plasmin-anti-plasmin complex, D-dimer, factor VIII, IL-2, CD40 ligand, E-selectin, 
Matrix metalloproteinase 3 and 9, plasminogen activator inhibitor, tissue factor, tissue factor pathway inhibitor, Von Willebrand factor and 
homocysteine. Analysis adjusted for age, gender, race, diabetes, any anti-hypertensive medication use, systolic blood pressure, smoking, 
creatinine and physical activity.
